Asterias Biotherapeutics intends to conduct public offering of stock

Bookrunner Raymond James raises funds for general corporate purposes

By Devika Patel

Knoxville, Tenn., May 9 – Asterias Biotherapeutics, Inc. said it plans to price a public sale of common stock and warrants with a 15% greenshoe.

Raymond James & Associates, Inc. is the bookrunner.

Proceeds will be used for general corporate purposes, including clinical trials, research and development, capital expenditures and working capital.

The Menlo Park, Calif., company is a subsidiary of BioTime, Inc., an Alameda, Calif., biotechnology company.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.